SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inches up on the BSE

19 Aug 2022 Evaluate

Lupin is currently trading at Rs. 689.15, up by 0.65 points or 0.09% from its previous closing of Rs. 688.50 on the BSE.

The scrip opened at Rs. 690.00 and has touched a high and low of Rs. 696.20 and Rs. 685.30 respectively. So far 13733 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 995.00 on 15-Sep-2021 and a 52 week low of Rs. 583.05 on 25-May-2022.

Last one week high and low of the scrip stood at Rs. 696.20 and Rs. 674.90 respectively. The current market cap of the company is Rs. 31315.62 crore.

The promoters holding in the company stood at 47.10%, while Institutions and Non-Institutions held 41.45% and 11.45% respectively.

Lupin has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), Rufinamide Tablets USP, 100 mg, 200 mg, and 400 mg, to market a generic equivalent of Banzel Tablets, 100 mg, 200 mg, and 400 mg, of Eisai Inc. The product will be manufactured at Lupin’s facility in Goa, India. Rufinamide Tablets (RLD Banzel) had estimated annual sales of $164 million in the U.S. (IQVIA MAT June 2022).

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2265.15 -112.75 (-4.74%)
11-May-2026 13:08 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.20
Dr. Reddys Lab 1293.20
Cipla 1314.50
Zydus Lifesciences 944.10
Lupin 2265.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×